Baird raised the firm’s price target on Stryker (SYK) to $405 from $378 and keeps an Outperform rating on the shares. The firm said 3Q was another solid quarter with global organic growth reaccelerating to the double-digits, orthopedic pricing turning positive for first time in a decade, and EPS growing at/above mid-teens.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: